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Raynaud’s phenomenon ++ -
Symmetric induration ++ -
Sclerodactyly ++ -
Facial involvement + - plaque-type and generalized
+linear
Systemic involvement ++ -
Antinuclear antibodies ++ + generalized and linear- 
plaque- type
Anticentromere antibodies + limited -
Antitopoisomerase I + diffuse -




CC: I have developed a scar on my forehead
HPI: 45 y.o. AA female with a 2 month h/o
an enlarging scar on her forehead, which has  become lighter, depressed and 
extremely pruritic  




Social History: works as a direct care provider in a group home, no recent 
illnesses, smoker, denies alcohol or recreational drug use 
Physical Exam: 1cm x 3.5cm hypo and hyperpigmented, atrophic linear 
patch on central forehead extending into the hairline
Differential Diagnosis: Discoid lupus, linear morphea, cicatraix, Parry-
Romberg syndrome, systemic sclerosis, scleredema, morphea profunda, 
chemical/toxin exposure, lichen sclerosis, linear melorheostosis
Diagnostic procedure: 3mm punch biopsy central forehead and hairline
Pathology: Dermal Sclerosis compatible with morphea
Laboratory:
 •  CBC: mild normocytic anemia
 •  BMP: normal
 • ANA: negative
 • SCL-70:<1.0 (normal)
Diagnosis: En Coup de Sabre
Therapeutic exercises - pelvic floor contraction and relaxation 
with emphasis on relaxation for downregulation, muscle stretching, 
and core stabilization
Manual Therapy:
•  Muscle energy techniques for pelvic obliquity
•  Trigger point release with ischemic compression
•  Scar tissue massage along cesarean scars
•  Modified Thiele massage for increased circulation, proprioception 
and relaxation
• ANA: negative
  –  Modified Thiele massage for increased circulation, 
proprioception and relaxation
Electrotherapy - Pathway MR-20 sEMG and Synergy software 
program utilized for assessment and visual feedback training for 
pelvic floor relaxation and coordination
Self-Care Education - patient education regarding 
pathophysiology, body mechanics, posture training, relaxation 
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MORPHEA
•  Inflammatory disease of the 
dermis and subcutaneous tissue 
characterized by dermal sclerosis
  –  Represents a localized form of 
scleroderma lacking internal 
organ involvement
•  Sporadic; familial cases reported
  –  Genetic susceptibility  -  
environmental triggers
  – No clear HLA association
•  Morphea
  –  Generalized
  – PLaque-like
  –  Linear
  – Morpheaform
PATHOGENESIS
•  Vascular changes
  –  Microvascular injury
    • Adhesion molecules expressed
    • Endothelial swelling
    • Thickening of basement membrane, 
               intimal hyperplasia
•  Activated T-cells stimulate connective tissue 
production by fibroblasts
  –  Pathologically enhanced collagen production by 
T-cell derived cytokines, IL-4 and TGF-B
PLAQUE-LIKE MORPHEA
•  Clinical
  –  Most frequent clinical presentation
  –  Elevated erythematous or violaceous, expanding 
plaque
  –  Central part of lesion becomes sclerotic and 
ivory-colored 
•  Course
  – Variable 3-5 years
  –  Post inflammatory hyperpigmentation
LINEAR MORPHEA
•  Clinical
  –  Linear, erythematous 
  –  Band-like or circular 
  –  Lower and upper extremities, frontal head, thorax
  – Involves fascia, muscle, tendon
•  Course
  –  Longer +/-progressive
EN COUP DE SABRE
•  Clinical
  –  Linear band of atraaophay
  –  Median or paramedian
  – Resembles a sabre cut
  – Multiple lesions rare
  – Facial atrophy may occur
  – May involve muscles, bones, meninges and brain
•  Course
  –  Longer and occasionally progressive
PARRY ROMBERG SYNDROME
• Severe variant linear morphea  or separate entity
  –  Hemifacial skin, tissue 
  –  Atrophy of subcutaneous fat
  – Muscles and bones of face 
  – Little or no sclerosis
  – Pathogenesis unknown
  – 10% epilepsy or neurological abnormatlities
•  Prognosis
  –  Although 10x more prevalent than systemic sclerosis, most cases resolve 
within 3 years
  –  10% develop functional limitations or disfigurement due to extent or 
location of disease
TREATMENT OF MORPHEA
• Topical and/or intralesional steroids
•  Systemic corticosteroids – inflammatory stages of morphea with rapidly 
progressive linear or disabling morphea
  –  Do not improve established sclerosis
•  Methotrexate- 15-20mg/wk – in acute phase
•  PCN- 30x10IU/dy 3-4 weeks helpful (5%)
•  Penicillamine– similarly effective, not used side effects
•  Vitamin Derivatives
  –  Acitretin 10-50mg/day localized scleroderma, response seen after months
  – Retinoids - inhibit TGF-B
  – Calcitriol – antiinflammatory  modulates fibroblast growth TGF-B
